Non-drug therapy for metabolic disturbances in abdominal obesity
Elizarov, A.N.; Razumov, A.N.; Frolkov, V.K.
Voprosy Kurortologii Fizioterapii i Lechebnoi Fizicheskoi Kultury 1: 21-23
2007
ISSN/ISBN: 0042-8787 PMID: 17402540 Document Number: 609651
Document emailed within 1 workday
Related Documents
Lizohub, V.H.; Hryshkova, Z.A. 2002: Hemodynamic and metabolic disturbances in patients with hypertension with and without obesity Likars'ka Sprava 2002(3-4): 38-42De Vries, A.P.; Bakker, S.J.; Gans, R.O. 2001: Abdominal obesity: metabolic complications and consequences for the liver Nederlands Tijdschrift Voor Geneeskunde 145(39): 1910-1911
Oldenburg, B.; Pijl, H. 2001: Abdominal obesity: metabolic complications and consequences for the liver Nederlands Tijdschrift Voor Geneeskunde 145(27): 1290-1294
Ascaso, J.F. 2008: Abdominal obesity, insulin resistance and metabolic and vascular risk Medicina Clinica 131(10): 380-381
Bunton, R.W. 1983: Reintroduction of anti-inflammatory drug therapy after drug-associated gastrointestinal disturbances New Zealand Medical Journal 96(726): 144
Miyata, Y.; Shimomura, I. 2016: Vitamin D, obesity, and diabetes:new technology toward drug development against metabolic diseases Clinical Calcium 26(3): 385-391
Jervell, J. 1973: Drug therapy of obesity Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 93(35): 2590-2591
Dickerson, L.M.; Carek, P.J. 2000: Drug therapy for obesity American Family Physician 61(7): 2131-2138; 2143
Sankhla, M.; Sharma, T.K.; Mathur, K.; Rathor, J.S.; Butolia, V.; Amita K Gadhok; Vardey, S.K.; Sinha, M.; G.G. Kaushik 2012: Relationship of Oxidative Stress with Obesity and its Role in Obesity Induced Metabolic Syndrome Clinical Laboratory 58(5-6): 385-392
Yamada-Goto, N.; Katsuura, G.; Ochi, Y.; Nakao, K. 2012: An approach toward CNS dysfunction associated with metabolic syndrome; implication of leptin, which is a key molecule of obesity, in depression associated with obesity Nihon Shinkei Seishin Yakurigaku Zasshi 32(5-6): 245-250
Suter, P.M.; Vetter, W. 2000: Drug therapy of obesity. Strategies for general practice Praxis 89(14): 575-585
Kamran, S.M.; Iftikhar, R.; Khan, A.; Altaf, M. 2014: Comparison of CAD risk factors in abdominal obesity versus general obesity with normal WC in adult males JPMA. Journal of the Pakistan Medical Association 64(4): 394-398
Panina, E.B.; Botvinnik, V.S. 1992: The role of autonomic dysfunction in the pathogenesis of lipid and lipoprotein metabolic disorders in patients with metabolic-alimentary obesity Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 92(5-12): 22-24
Minarcíková, I. 2003: Long-term drug therapy of obesity in 2002--pharmacoeconomic aspects Ceska a Slovenska Farmacie: Casopis Ceske Farmaceuticke Spolecnosti a Slovenske Farmaceuticke Spolecnosti 52(5): 258-261
Müting, D. 1978: Metabolic risk factors and their field of action. Incidence and therapy of hypertension, hyperuricemia, hyperlipidemia, diabetes mellitus, nicotine and alcohol abuse and obesity Fortschritte der Medizin 96(25): 1319-1322
Baranowska, B. 1995: Neuroendocrine disturbances in obesity Polski Tygodnik Lekarski Suppl 1: 26-28
Liljedahl, G.; Birke, G.; Carlsson, L.A.; von Euler, U. 1971: Metabolic disturbances in burns Nordisk Medicin 86(30): 909
Popovic, M.; Radivojevic, B.; Micic, R.; Tosic, S. 1971: Metabolic disturbances in pyloric stenosis Vojnosanitetski Pregled 28(11): 587-591
Lumholtz, I.B. 1976: Drug information for nurses. Obesity; therapeutic main group: anorectics, appetite depressants. 3. Complications of obesity Sygeplejersken 76(40): 11
Rodonezhskaia, E.V.; Kharchenko, N.V. 2001: Correction of metabolic disturbances in patients with cholestasis Likars'ka Sprava 2001(3): 148-149